Ovarian cancer
Conditions
Interventions
one arm:nab-paclitaxel in combination with carboplati
Sponsors
Qilu Hospital of Shandong University
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Age 18~70 years old; 2. Histologic diagnosis of epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal carcinoma; 3. Stage IC to IV according to International Federation of Gynecology and Obstetrics staging system; 4. Imaging assessment according to RECIST1.1, measurable lesion,or evaluating CA-125 according to GCIG; 5. Neoadjuvant chemotherapy can be given before surgery to patients whose tumors are too large or whose lesions have a wide range and are not expected to achieve ideal tumor cell reduction; 6. Eastern Cooperative Oncology Group performance status = 3 months; 8.Left ventricular ejection fraction(LVEF)>= 50%; 9. Bone marrow function: Neutrophil >= 1.5 x 10^9/L, platelet >= 100 x 10^9/L, hemoglobin >= 90g/L; 10. Liver and renal function:serum creatinine <= 1.5 times the upper limit of normal value, AST and ALT <= 2.5 times the upper limit of normal value or 5 times the upper limit of normal value with liver metastasis, total bilirubin <= 1.5 times the upper limit of normal value or <= 2.5 times the upper limit of normal value with Gilbert's Syndrom; 11. Subjects of childbearing age must agree to use effective contraception during the study period, Serum or urine pregnancy tests must be negative in women of childbearing age, Non-lactation patients; 12. Sign informed Consent.
Exclusion criteria
Exclusion criteria: 1. Low grade malignant potential tumor of ovary; 2. Previous chemotherapy of abdomen or pelvis; 3. Planning chemotherapy of abdomen or pelvis; 4. Previous or current presence of heart disease with a New York Heart Association grade 2 or above; 5. Malignant neoplasia (not including non-melanoma skin cancer or in-situ carcinoma of the uterine cervix, provided they are being adequately treated); 6. Uncontrolled systemic infections require antiinfective treatment; 7. Known to be allergic, highly sensitive or intolerant to investigational drugs or their excipients; 8. Previous sensory or motor neuropathy >= 2 grade; 9. Patient's inability to access the center determined by investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| objective response rate; | — |
Countries
China
Contacts
Public ContactJie Jiang
Outcome results
None listed